Authors:
Vangani, V
Drage, J
Mehta, J
Mathew, AK
Duhamel, J
Citation: V. Vangani et al., Maleated ethylene-propylene random copolymers: Determination of the microstructure and association level by fluorescence spectroscopy, J PHYS CH B, 105(21), 2001, pp. 4827-4839
Authors:
Sirohi, B
Powles, R
Mehta, J
Treleaven, J
Raje, N
Kulkarni, S
Rudin, C
Bhagwati, N
Horton, C
Saso, R
Singhal, S
Parikh, P
Citation: B. Sirohi et al., The implication of compromised renal function at presentation in myeloma -Similar outcome in Patients who receive high-dose therapy: A single-centerstudy of 251 previously untreated patients, MED ONCOL, 18(1), 2001, pp. 39-50
Authors:
Quilitz, RE
Arnold, AD
Briones, GR
Dix, SP
Ippoliti, C
Kennedy, LD
Lucich, JL
Mehta, J
Peters, BG
Tice, DS
Citation: Re. Quilitz et al., Practice guidelines for lipid-based amphotericin B in stem cell transplantrecipients, ANN PHARMAC, 35(2), 2001, pp. 206-216
Authors:
Safdar, A
van Rhee, F
Henslee-Downey, JP
Singhal, S
Mehta, J
Citation: A. Safdar et al., Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxison incidence and outcome, BONE MAR TR, 28(9), 2001, pp. 873-878
Authors:
Mehta, J
Oyama, Y
Winter, J
Williams, S
Tallman, M
Singhal, S
Villa, M
Shook, T
Burt, R
Traynor, A
Soff, G
Masarik, S
Ramsey, G
Gordon, L
Citation: J. Mehta et al., CD34(+) cell collection efficiency does not correlate with the pre-leukapheresis hematocrit, BONE MAR TR, 28(6), 2001, pp. 597-601
Authors:
Sirohi, B
Powles, R
Kulkarni, S
Rudin, C
Saso, R
Lal, R
Singhal, S
Mehta, J
Horton, C
Treleaven, J
Citation: B. Sirohi et al., Comparison of new patients with Bence-Jones, IgG and IgA myeloma receivingsequential therapy: the need to regard these immunologic subtypes as separate disease entities with specific prognostic criteria, BONE MAR TR, 28(1), 2001, pp. 29-37
Authors:
Chiang, KY
Van Rhee, F
Godder, K
Bridges, K
Adams, S
Mehta, J
Henslee-Downey, PJ
Citation: Ky. Chiang et al., Allogeneic bone marrow transplantation from partially mismatched related donors as therapy for primary induction failure acute myeloid leukemia, BONE MAR TR, 27(5), 2001, pp. 507-510
Citation: S. Singhal et al., Hematopoietic reconstitution by transplantation of stem cells from bone marrow or blood., N ENG J MED, 344(21), 2001, pp. 1641-1641
Authors:
Sirohi, B
Powles, R
Kulkarni, S
Rudin, C
Saso, R
Rigg, A
Horton, C
Singhal, S
Mehta, J
Treleaven, J
Citation: B. Sirohi et al., Glomerular filtration rate prior to high-dose melphalan 200 mg/m(2) as a surrogate marker of outcome in patients with myeloma, BR J CANC, 85(3), 2001, pp. 325-332
Authors:
Badros, A
Barlogie, B
Morris, C
Desikan, R
Martin, SR
Munshi, N
Zangari, M
Mehta, J
Toor, A
CottlerFox, M
Fassas, A
Aniassie, E
Schichman, S
Tricot, G
Citation: A. Badros et al., High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions (vol 97, pg 2574, 2001), BLOOD, 98(2), 2001, pp. 271-271
Authors:
Singhal, S
Powles, R
Treleaven, J
Kulkarni, S
Sirohi, B
Horton, C
Millar, B
Shepherd, V
Tait, D
Saso, R
Rowland, A
Long, S
Mehta, J
Citation: S. Singhal et al., A low CD34(+) cell dose results in higher mortality and poorer survival after blood or marrow stem cell transplantation from HLA-identical siblings: should 2 x 10(6) CD34(+) cells/kg be considered the minimum threshold?, BONE MAR TR, 26(5), 2000, pp. 489-496
Authors:
Singhal, S
Safdar, A
Chiang, KY
Godder, K
van Rhee, F
Garner, F
Foster, B
Dubovsky, D
Henslee-Downey, PJ
Mehta, J
Citation: S. Singhal et al., Non-myeloablative allogeneic transplantation ('microallograft') for refractory myeloma after two preceding autografts: feasibility and efficacy in a patient with active aspergillosis, BONE MAR TR, 26(11), 2000, pp. 1231-1233
Authors:
Powles, R
Sirohi, B
Kulkarni, S
Bhagwati, N
Saso, R
Raje, N
Horton, C
Singhal, S
Mehta, J
Treleaven, J
Citation: R. Powles et al., Acute lymphoblastic leukaemia-type intensive chemotherapy to eliminate minimal residual disease after high-dose melphalan and autologous transplantation in multiple myeloma - a phase I/II feasibility and tolerance study of 17 patients, BONE MAR TR, 25(9), 2000, pp. 949-956
Authors:
Desikan, KR
Tricot, G
Dhodapkar, M
Fassas, A
Siegel, D
Vesole, DH
Jagannath, S
Singhal, S
Mehta, J
Spoon, D
Anaissie, E
Barlogie, B
Munshi, N
Citation: Kr. Desikan et al., Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone, BONE MAR TR, 25(5), 2000, pp. 483-487
Authors:
Singhal, S
Powles, R
Kulkarni, S
Treleaven, J
Sirohi, B
Millar, B
Shepherd, V
Saso, R
Rowland, A
Long, S
Cabral, S
Horton, C
Mehta, J
Citation: S. Singhal et al., Comparison of marrow and blood cell yields from the same donors in a double-blind, randomized study of allogeneic marrow vs blood stem cell transplantation, BONE MAR TR, 25(5), 2000, pp. 501-505
Authors:
Sirohi, B
Powles, R
Treleaven, J
Mainwaring, P
Kulkarni, S
Pandha, H
Bhagwati, N
Horton, C
Singhal, S
Mehta, J
Citation: B. Sirohi et al., The role of autologous transplantation in patients with multiple myeloma aged 65 years and over, BONE MAR TR, 25(5), 2000, pp. 533-539
Authors:
Kulkarni, S
Powles, R
Treleaven, J
Singhal, S
Horton, C
Sirohi, B
Bhagawati, N
Tait, D
Saso, R
Killick, S
Pinkerton, R
Atra, A
Meller, S
Mehta, J
Citation: S. Kulkarni et al., Melphalan/TBI is not more carcinogeneic than cyclophosphamide/TBI for transplant conditioning: follow-up of 725 patients from a single centre over a period of 26 years, BONE MAR TR, 25(4), 2000, pp. 365-370
Authors:
Powles, R
Mehta, J
Kulkarni, S
Treleaven, J
Millar, B
Marsden, J
Shepherd, V
Rowland, A
Sirohi, B
Tait, D
Horton, C
Long, S
Singhal, S
Citation: R. Powles et al., Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial, LANCET, 355(9211), 2000, pp. 1231-1237
Authors:
Saso, R
Kulkarni, S
Mitchell, P
Treleaven, J
Swansbury, GJ
Mehta, J
Powles, R
Ashley, S
Kuan, A
Powles, T
Citation: R. Saso et al., Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma, BR J CANC, 83(1), 2000, pp. 91-94